Cargando…
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247052/ http://dx.doi.org/10.1186/bcr3025 |
| _version_ | 1782220032734920704 |
|---|---|
| author | Manso, L Ciruelos, E Codes, M De la Haba, J Galan, A Baena, J Jaen, A Gil, M Murias, A Blancas, I Gonzalez, E Perez, D Bayo, JL Mel, J Garcia-Martinez, E Cubedo, R Salvador, J |
| author_facet | Manso, L Ciruelos, E Codes, M De la Haba, J Galan, A Baena, J Jaen, A Gil, M Murias, A Blancas, I Gonzalez, E Perez, D Bayo, JL Mel, J Garcia-Martinez, E Cubedo, R Salvador, J |
| author_sort | Manso, L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3247052 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-32470522011-12-29 Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy Manso, L Ciruelos, E Codes, M De la Haba, J Galan, A Baena, J Jaen, A Gil, M Murias, A Blancas, I Gonzalez, E Perez, D Bayo, JL Mel, J Garcia-Martinez, E Cubedo, R Salvador, J Breast Cancer Res Poster Presentation BioMed Central 2011 2011-11-16 /pmc/articles/PMC3247052/ http://dx.doi.org/10.1186/bcr3025 Text en Copyright ©2011 Manso et al. |
| spellingShingle | Poster Presentation Manso, L Ciruelos, E Codes, M De la Haba, J Galan, A Baena, J Jaen, A Gil, M Murias, A Blancas, I Gonzalez, E Perez, D Bayo, JL Mel, J Garcia-Martinez, E Cubedo, R Salvador, J Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title | Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title_full | Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title_fullStr | Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title_full_unstemmed | Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title_short | Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| title_sort | prognostic value of a high level of circulating endothelial cells in patients with her2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247052/ http://dx.doi.org/10.1186/bcr3025 |
| work_keys_str_mv | AT mansol prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT ciruelose prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT codesm prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT delahabaj prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT galana prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT baenaj prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT jaena prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT gilm prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT muriasa prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT blancasi prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT gonzaleze prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT perezd prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT bayojl prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT melj prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT garciamartineze prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT cubedor prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy AT salvadorj prognosticvalueofahighlevelofcirculatingendothelialcellsinpatientswithher2recurrentormetastaticbreastcancertreatedwithbevacizumabincombinationwithpaclitaxelandgemcitabineasfirstlinetherapy |